It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.
Zachariah Thomas, Cindy Y. Jiang, Patrick Speck et al.· JAMA Network Open· 0 citations
This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Joud Hajjar, B. Stephen, A. Aaroe et al.· Journal of Immunotherapy and...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.